Interféron et hématologie

作者: L. Lacotte-Thierry , F. Guilhot

DOI: 10.1016/S0248-8663(02)00662-8

关键词:

摘要: Resume Propos. -Les interferons (IFN) alpha sont des cytokines utilisees depuis plusieurs annees dans le traitement de certaines hemopathies, a la fois myeloides et lymphoides. Les IFN une famille polypeptides produits par les cellules eucaryotes en reponse divers agents stimulants. premiers essais l'utilisation cette cytokine chez l'homme ont ete realisees H. Strander daps 1965–1970. proprietes antivirales, antiproliferatives immunomodulatrices. La mise disposition cliniciens molecules recombinant produites genie genetique environ vingtaine d'annees, permis realiser nombreux therapeutiques. En hematologie, l'interet clinique FIFN surtout etudie syndromes myeloproliferatifs lymphoproliferatifs chroniques. Certaines indications ce jour bien demontrees. Cependant, l'impact prise charge therapeutique hemopathies rapport au conventionnel reste controverse. Parallelement, frequency effets secondaires traitements son coat doivent etre pris consideration. Actualites points forts. therapeutiques realises durant ces derrieres provee dans, essentiellement, deux maladies : d'une part, leucemie myeloide chronique avec obtention remissions cytogenetiques et, d'autre lymphome malin non Hodgkinien type folliculaire. Dans d'autres place l'IFN discutee. Perspectives projets. -L'avenir semble lid association avecles nouveaux traitements, dont l'efficacite superiority cependant C'est cas ou pent associe l'aracytine aux inhibiteurs tyrosine kinase. lymphomes malins hodgkinien, etudes concernent l'association anticorps monoclonaux, particulier l'anticorps anti-CD-20.

参考文章(44)
Hagop Kantarjian, Charles Sawyers, Andreas Hochhaus, Francois Guilhot, Charles Schiffer, Carlo Gambacorti-Passerini, Dietger Niederwieser, Debra Resta, Renaud Capdeville, Ulrike Zoellner, Moshe Talpaz, Brian Druker, None, Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia The New England Journal of Medicine. ,vol. 346, pp. 645- 652 ,(2002) , 10.1056/NEJMOA011573
A Rohatiner, J Radford, D Deakin, H Earl, S B Love, O Price, A Wilson, T A Lister, A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma British Journal of Cancer. ,vol. 85, pp. 29- 35 ,(2001) , 10.1054/BJOC.2001.1822
John M. Goldman, Brian J. Druker, Chronic myeloid leukemia: current treatment options Blood. ,vol. 98, pp. 2039- 2042 ,(2001) , 10.1182/BLOOD.V98.7.2039
Dadvid Cunningham, Ray Powles, James Malpas, Noopur Raje, Sarah Milan, Christine Viner, Anna Montes, Tamas Hickish, Marianne Nicolson, Paul Johnson, Jennifer Treleaven, Julian Raymond, Martin Gore, A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results British Journal of Haematology. ,vol. 102, pp. 495- 502 ,(1998) , 10.1046/J.1365-2141.1998.00795.X
B. Rotoli, A. De Renzo, F. Frigeri, S. Buffardi, R. Marceno, A. M. Cavallaro, P. Ruggeri, V. Liso, P. Musto, A. Andriani, V. Callea, M. Pizzuti, E. Iannitto, R. Cimino, S. Molica, P. Citarrella, C. Musolino, S. Guarino, G. Lucarelli, A. Espinosa, L. Del Vecchio, A Phase II Trial on Alpha-Interferon α IFN) Effect in Patients with Monoclonal IgM Gammopathy Leukemia & Lymphoma. ,vol. 13, pp. 463- 469 ,(1994) , 10.3109/10428199409049636
David G. Savage, Karen H. Antman, Imatinib Mesylate — A New Oral Targeted Therapy The New England Journal of Medicine. ,vol. 346, pp. 683- 693 ,(2002) , 10.1056/NEJMRA013339
FX Mahon, X Delbrel, P Cony-Makhoul, C Faberes, JM Boiron, C Barthe, C Bilhou-Nabera, A Pigneux, G Marit, J Reiffers, Follow-Up of Complete Cytogenetic Remission in Patients With Chronic Myeloid Leukemia After Cessation of Interferon Alfa Journal of Clinical Oncology. ,vol. 20, pp. 214- 220 ,(2002) , 10.1200/JCO.20.1.214
E. Lengfelder, U. Berger, R. Hehlmann, Interferon α in the treatment of polycythemia vera Annals of Hematology. ,vol. 79, pp. 103- 109 ,(2000) , 10.1007/S002770050563
Ayalew Tefferi, Michelle A. Elliott, Soo-Young Yoon, Chin-Yang Li, Ruben A. Mesa, Timothy G. Call, Angela Dispenzieri, Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood. ,vol. 97, pp. 1896- 1897 ,(2001) , 10.1182/BLOOD.V97.6.1896
M. Bentley, K. Taylor, A. Grigg, H. Kronenberg, J. Gibson, I. Bunce, P. Eliadis, T. Olsen, S. Wright, D. Taylor, R. Rodwell, Long-term interferon-alpha 2A does not induce sustained hematologic remission in younger patients with essential thrombocythemia. Leukemia & Lymphoma. ,vol. 36, pp. 123- 128 ,(1999) , 10.3109/10428199909145955